HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
0.8760
-0.1540 (-14.95%)
At close: Jun 29, 2026, 4:00 PM EDT
0.8800
+0.0040 (0.46%)
After-hours: Jun 29, 2026, 7:49 PM EDT
HCW Biologics Revenue
HCW Biologics had revenue of $6.54M in the quarter ending March 31, 2026, with 129,080.67% growth. This brings the company's revenue in the last twelve months to $6.59M, up 356.16% year-over-year. In the year 2025, HCW Biologics had annual revenue of $54.23K, down -97.89%.
Revenue (ttm)
$6.59M
Revenue Growth
+356.16%
P/S Ratio
0.94
Revenue / Employee
$188,348
Employees
35
Market Cap
6.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.23K | -2.51M | -97.89% |
| Dec 31, 2024 | 2.57M | -275.00K | -9.68% |
| Dec 31, 2023 | 2.84M | -3.88M | -57.72% |
| Dec 31, 2022 | 6.72M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 6.50M |
| Immuron | 4.99M |
| Xenetic Biosciences | 3.19M |
| Aspire Biopharma Holdings | 34.56K |
| Ernexa Therapeutics | 1,000.00 |
HCWB News
- 6 hours ago - Hcw Biologics Inc trading halted, news pending - TheFly
- 3 days ago - HCW Biologics announces 1-for-6 reverse stock split - TheFly
- 3 days ago - HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 - GlobeNewsWire
- 11 days ago - HCW Biologics Registration statement: Registration filing - Filings
- 13 days ago - HCW Biologics announces data from first two dose cohorts of HCW9302 trial - TheFly
- 13 days ago - HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata - GlobeNewsWire
- 14 days ago - HCW Biologics Transcript: AGM 2026 - Transcripts
- 21 days ago - HCW Biologics registers to sell 5.69M shares of common stock for holders - TheFly